The side effect profile is generally similar, but there are some considerations specific to compounded versions
The FDA has approved semaglutide 2.4 mg for metabolic dysfunction-associated steatohepatitis (MASH), a condition in which any alcohol consumption worsens hepatic inflammation
And the latest research paints a compelling picture: In 2022, researchers found that creatine supplementation enhanced concentrations in the brain by 15%, possibly leading to improved cognitive acuity
Results May Vary: Any weight loss outcome figures referenced in this article are based on self-reported data from altRx customers and reflect altRx's own published outcome language
Semaglutide has been shown to improve lipid profiles by reducing LDL cholesterol levels and increasing HDL cholesterol levels, thereby positively impacting cardiovascular health
Risks and Considerations with Compounded Semaglutide The FDA has documented numerous safety concerns with compounded semaglutide, including over 520 reported adverse events as of April 2025
:quality(75):max_bytes(102400)/https://assets.iprofesional.com/assets/jpg/2025/04/594306.jpg)
![Noncovalent Binding between Guanidinium and Anionic Groups: Focus on Biological- and Synthetic-Based Arginine/Guanidinium Interactions with Phosph[on]ate and Sulf[on]ate Residues](https://pubs.acs.org/cms/10.1021/cr040603j/asset/images/medium/cr040603jf1.gif)
